AAD: Significant benefits seen for brepocitinib 30 mg in dermatomyositis
by Elana GotkineFor adults with dermatomyositis, brepocitinib, an oral tyrosine kinase 2/Janus kinase 1 inhibitor, demonstrates significant benefits at a 30-mg dose compared with placebo, according to
Updated on: April 10,2026
AAD: Significant benefits seen for brepocitinib 30 mg in dermatomyositis
by Elana GotkineFor adults with dermatomyositis, brepocitinib, an oral tyrosine kinase 2/Janus kinase 1 inhibitor, demonstrates significant benefits at a 30-mg dose compared with placebo, according to
Updated on:April 10,2026
